Earnings Summary

Fulcrum Therapeutics Inc’s revenue jumped 27.15% since last year same period to $0.87Mn in the Q4 2023. On a quarterly growth basis, Fulcrum Therapeutics Inc has generated 14.76% jump in its revenue since last 3-months.

Fulcrum Therapeutics Inc’s net profit fell -4.77% since last year same period to $-24.76Mn in the Q4 2023. On a quarterly growth basis, Fulcrum Therapeutics Inc has generated -3.08% fall in its net profits since last 3-months.

Fulcrum Therapeutics Inc’s net profit margin jumped 17.61% since last year same period to -2842.25% in the Q4 2023. On a quarterly growth basis, Fulcrum Therapeutics Inc has generated 10.18% jump in its net profit margins since last 3-months.

Fulcrum Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.44 - a -2.33% fall from last quarter’s estimates.

Fulcrum Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.44.

Fulcrum Therapeutics Inc’s earning per share (EPS) jumped 20% since last year same period to -0.4 in the Q4 2023. This indicates that the Fulcrum Therapeutics Inc has generated 20% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Fulcrum Therapeutics Inc’s return on assets (ROA) stands at -0.29.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Fulcrum Therapeutics Inc’s return on equity (ROE) stands at -0.45.